| Title |
Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery Disease
|
|---|---|
| Published in |
Cardiovascular Drugs and Therapy, December 2012
|
| DOI | 10.1007/s10557-012-6427-8 |
| Pubmed ID | |
| Authors |
João Tomé-Carneiro, Manuel Gonzálvez, Mar Larrosa, María J. Yáñez-Gascón, Francisco J. García-Almagro, José A. Ruiz-Ros, Francisco A. Tomás-Barberán, María T. García-Conesa, Juan Carlos Espín |
| Abstract |
The grape and wine polyphenol resveratrol exerts cardiovascular benefits but evidence from randomized human clinical trials is very limited. We investigated dose-depending effects of a resveratrol-containing grape supplement on stable patients with coronary artery disease (CAD) treated according to currently accepted guidelines for secondary prevention of cardiovascular disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 199 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 1% |
| Spain | 2 | 1% |
| South Africa | 1 | <1% |
| Brazil | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 192 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 45 | 23% |
| Student > Master | 24 | 12% |
| Researcher | 22 | 11% |
| Student > Postgraduate | 15 | 8% |
| Student > Ph. D. Student | 15 | 8% |
| Other | 45 | 23% |
| Unknown | 33 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 26% |
| Agricultural and Biological Sciences | 31 | 16% |
| Biochemistry, Genetics and Molecular Biology | 17 | 9% |
| Nursing and Health Professions | 14 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
| Other | 26 | 13% |
| Unknown | 48 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2023.
All research outputs
#978,725
of 26,017,215 outputs
Outputs from Cardiovascular Drugs and Therapy
#10
of 785 outputs
Outputs of similar age
#7,301
of 292,215 outputs
Outputs of similar age from Cardiovascular Drugs and Therapy
#1
of 8 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 785 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,215 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them